Jump to content

Recommended Posts

Paul Edwards

JNJ-56021927 (formerly known as ARN-509) is an androgen receptor antagonist.    Some prostate cancer cells require androgens for growth.  JNJ-56021927 prevent androgens from binding to the prostate cancer cells’ androgen receptors.

 

JNJ-56021927 is not as advanced in its development as enzalutamide (Brand name Xtandi).   Results from initial clinical trials suggest that JNJ-56021927 may be more potent and effective than enzalutamide.

 

A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer is being conducted. 

 

Details of this trial can be found by clicking on this link: https://clinicaltrials.gov/ct2/show/NCT02257736

 

This clinical trial is being conducted at a number of hospitals in most Australian states.  I am aware that the Royal Melbourne Hospital has commenced recruitment of patients for this trial.  I'm not aware of the recruitment status of the other Australian sites but I expect that these sites will commence recruitment shortly, if they are not already doing so.

 

There will be 2 arms of the trial.

 

Patients on the 1st arm will receive Abiraterone, Prednisone and JNJ-56021927.

 

Patients on the 2nd arm will receive Abiraterone, Prednisone and a placebo.

 

 

Link to post
Share on other sites
  • 3 months later...

Hi Paul,

 

Thanks for the post.  I have followed the link and (I hope) registered to be part of the trial.  I have nominated the site at Woolloongabba, which I believe should be either Princess Alexandra Hospital or the APCRC or both, but I am yet to hear anything back.  I have also put my oncologist onto it, and she is attempting to follow up for me, so here's hoping.  I will post on the Forum once I hear anything back.

 

Cheers

 

Kerry Drinkwater

Link to post
Share on other sites
  • 2 weeks later...
Paul Edwards

The trial is being run at Princess Alexandra Hospital with Dr Elizabeth McCaffery as the Principal Investigator.  Jennifer Suffolk  (phone 07 3176 7825) is the Clinical Trials Co-Ordinator at PA. You'll need a referral from your oncologist or GP.

Link to post
Share on other sites

Thanks all, I am off for a CT on Tuesday to make sure they can map my bone lesions as a precursor to entry to the trial.  Interestingly the lesions showed up on both the PET scan I had at the Wesley with Gallium 68 and associated CT, but they want a new CT to confirm and then they will do their own CT prior to me being "randomised"  in the trial groups.  I will keep you all posted of developments.

Link to post
Share on other sites
×
×
  • Create New...